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Summary
Checkpoints that control Myc-mediated proliferation and apoptosis are bypassed during tumorigenesis. Genes encoding
polyamine biosynthetic enzymes are overexpressed in B cells from E-Myc transgenic mice. Here, we report that disabling
one of these Myc targets, Ornithine decarboxylase (Odc), abolishes Myc-induced suppression of the Cdk inhibitors p21Cip1
and p27Kip1, thereby impairing Myc’s proliferative, but not apoptotic, response. Moreover, lymphoma development was
markedly delayed in E-Myc;Odc+/− transgenic mice and in E-Myc mice treated with the Odc inhibitor difluoromethylor-
nithine (DFMO). Strikingly, tumors ultimately arising in E-Myc;Odc+/− transgenics lacked deletions of Arf, suggesting that
targeting Odc forces other routes of transformation. Therefore, Odc is a critical Myc transcription target that regulates
checkpoints that guard against tumorigenesis and is an effective target for cancer chemoprevention.S I G N I F I C A N C E
The ability of oncogenes to provoke cancer is harnessed by regulators that control cell proliferation or induce apoptosis, and bypass
of these checkpoints is a hallmark of malignancies. Myc oncoproteins are overexpressed in w70% of all cancers and induce
numerous transcription targets that regulate cell growth, metabolism, and the ribosome machinery. In this report, we show that one
select Myc target, Ornithine decarboxylase (Odc), the rate-limiting enzyme of polyamine biosynthesis, is a critical downstream
regulator of Myc’s ability to provoke accelerated growth and cancer. Odc heterozygosity or inhibition of Odc enzyme activity is
shown to affect checkpoints bypassed during Myc-induced tumorigenesis, establishing a mechanism by which chemoprevention
strategies targeting Odc can prevent the development of cancer.Introduction
The Myc family of oncogenes (c-myc, N-myc, and L-myc) is
activated in w70% of human cancer by direct means such as
translocations or amplifications or indirectly in response to al-
terations in upstream signaling pathways or tumor suppres-
sors. To determine their roles in human cancer, transgenic mice
have been engineered to express Myc genes in a variety of
tissues, including the skin (Pelengaris et al., 1999), pancreas
(Pelengaris et al., 2002), and prostate (Ellwood-Yen et al.,
2003), and in all of these scenarios, enforced Myc expression
provokes lethal malignancies. The E-Myc transgenic mouse
was one of the first mouse models of cancer (Adams et al.,
1985), and overexpression of c-myc in the B cells of these mice
by the immunoglobulin heavy chain enhancer (E) mimics the
overexpression of MYC in human Burkitt’s lymphoma (BL) that
harbors MYC:Ig translocations (Dalla-Favera et al., 1982). Im-
portantly, the genetic alterations that accompany the develop-
ment of B cell lymphomas in E-Myc transgenics mimic those
that occur in human BL (Eischen et al., 1999; Lindstrom et al.,
2001; Wilda et al., 2004), underscoring the use of this trans-CANCER CELL : MAY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.genic as an important in vivo tool for understanding the molec-
ular pathogenesis of Myc-driven cancers and as a platform to
test agents that prevent or treat established disease.
Overexpression of Myc at levels found in cancer is sufficient
to drive normal quiescent cells into cycle and to accelerate
their rates of cell cycle traverse (Bouchard et al., 1998). These
responses are, at least in part, dependent upon Myc’s ability
to downregulate the expression of the cyclin-dependent kinase
(Cdk) inhibitors p27Kip1 and p21Cip1 (Baudino et al., 2003; Her-
old et al., 2002; Vlach et al., 1996). However, cells respond to
this hyperproliferative response by activating apoptosis (Askew
et al., 1991; Evan et al., 1992), through the agency of the Arf-
p53 tumor suppressor pathway (Eischen et al., 1999; Zindy et
al., 1998), by suppressing the expression of the antiapoptotic
proteins Bcl-2 and/or Bcl-XL (Eischen et al., 2001a) and/or by
various other pathways (Nilsson and Cleveland, 2003). Notably,
bypass of these cell cycle checkpoints and apoptotic path-
ways is a hallmark of Myc-driven cancers, and their disruption
in transgenic and knockout mouse models markedly acceler-
ates Myc-induced tumorigenesis (Baudino et al., 2003; Egle et
al., 2004; Eischen et al., 1999; Eischen et al., 2001b; MartinsDOI 10.1016/j.ccr.2005.03.036 433
A R T I C L Eand Berns, 2002; Pelengaris et al., 2002; Schmitt et al., 1999;
Schmitt et al., 2002; Strasser et al., 1990).
Myc proteins are basic helix-loop-helix leucine-zipper (bHLH-
Zip) transcription factors whose function relies on their dimer-
ization with a small bHLH-Zip transcription factor coined Max
to bind DNA. Myc-Max complexes transactivate genes carry-
ing their recognition sequence CAYGTG, yet when in a ternary
complex with other transcriptional factors such as Miz-1, Myc
can repress some target genes (Eisenman, 2001), in particular
the Cdk inhibitors p21Cip1 and p15Ink4b (Herold et al., 2002;
Staller et al., 2001). Which specific targets contribute to Myc’s
diverse biological effects is a real challenge, as recent genome-
wide scanning approaches have shown as many as one-tenth
of all genes carry CAYGTG (E box) sequences and thus may
be bound by Myc-Max complexes (Patel et al., 2004).
Odc was one of the first identified transactivation targets of
Myc (Bello-Fernandez et al., 1993; Wagner et al., 1993), and
it encodes the rate-limiting enzyme in polyamine biosynthesis
(Cohen, 1997). Polyamines are positively charged small mole-
cules present in all living organisms that bind to and stabilize
negatively charged cellular macromolecules, including nucleic
acids, phospholipids, and proteins. However, polyamines also
perform essential specific functions, for example in the joining
of Okazaki fragments during DNA replication, as modifiers of
ion transport channels and as regulators of protein translation
(Gerner and Meyskens, 2004). Given their broad roles, intracel-
lular polyamine levels are kept under tight control in cells
through transport, export, synthesis, and catabolism (Cohen,
1997). Odc converts L-ornithine into putrescine, which is then
converted into spermidine and then spermine by dedicated
synthases. Odc has been used for a number of years as a sur-
rogate marker for Myc function and fulfills all criteria for a bona
fide Myc target, as it contains conserved CAYGTG E boxes
(Bello-Fernandez et al., 1993), is bound by Myc-Max in growth-
stimulated cells (Bello-Fernandez et al., 1993; Nilsson et al.,
2004a), and can be conditionally activated by Myc indepen-
dent of de novo protein synthesis (Wagner et al., 1993). How-
ever, the importance of Odc to Myc-induced apoptosis, cell
proliferation, and tumorigenesis has not been evaluated in vivo.
Odc is essential for mouse development, as Odc−/− blasto-
cysts die shortly after implantation (Pendeville et al., 2001), and
treatment of pregnant mice with α-DFMO, an irreversible inhibi-
tor of ODC, leads to resorption of the embryos by embryonic
day 5–8 (Fozard et al., 1980). Nonetheless, Odc+/− mice are
overtly normal (Pendeville et al., 2001), and chronic treatment
of adult wild-type (wt) mice with DFMO is well tolerated (Lan
et al., 2000). Thus, by using Odc+/− mice and DFMO as tools,
we evaluated the role of Odc in Myc-driven tumorigenesis in
the E-Myc transgenic mouse model. Here, we report that acti-
vation of Odc is a hallmark of B cell lymphomas arising in these
mice and in human BL. Importantly, impairing Odc disables
Myc’s ability to downregulate Cdk inhibitors, alters the route
of Myc-induced transformation, and markedly delays Myc-
induced lymphomagenesis. Collectively, these findings support
the notion of targeting Odc in cancer chemoprevention.
Results
Myc induces the polyamine biosynthetic pathway in vivo
Biased and unbiased analyses of cell lines engineered to over-
express c-Myc have indicated that Odc (Bello-Fernandez et al.,4341993) and the genes encoding S-adenosylmethionine decar-
boxylase (Amd1) and Spermidine synthase (Srm) (Myc target
gene database, http://www.myccancergene.org) are Myc tar-
get genes. To test the scope of the response of polyamine met-
abolic enzymes to Myc in vivo, we submitted total RNA of
B220+ splenic B cells from 6-week-old precancerous E-Myc
transgenic mice and their wt littermates to gene-chip analysis
(using Affymetrix 430A gene arrays) and clustered all of the
genes of the pathway (Supplemental Figure S1 available in the
Supplemental Data with this article online) that were present
on the chip (Figure 1A). These findings were then confirmed by
real-time PCR with total RNA from both spleen and bone mar-
row-derived B cells (Figure 1B). Notably, the expression of odc,
amd1, srm, and spermine synthase (sms) were all elevated in
B cells of E-Myc transgenic mice, whereas mRNAs encoding
enzymes in the catabolic arm of the pathway, spermine/sper-
midine N-acetyltransferase (sat1) and spermine oxidase (smox)
were generally repressed in E-Myc B cells (Figures 1A and
1B). The sole exception was the induction of polyamine oxi-
dase (paox, Figure 1B), yet in the presence of reduced levels
of sat1, which generates substrates for paox (Figure S1), this
is a futile response. Therefore, Myc coordinately regulates en-
zymes of the polyamine metabolic pathway in a manner that
should elevate polyamine levels in B cells. Indeed, direct mea-
surements of polyamine levels demonstrated that elevated
levels of putrescine, spermidine, and spermine were hallmarks
of E-Myc transgenic B cells (see below, Figure 3).
Odc overexpression is a hallmark
of Myc-induced lymphoma
Overexpression of Odc is sufficient to transform immortal fibro-
blast cells (Auvinen et al., 1992) and to provoke benign papillo-
mas in the skin of Odc transgenic mice (Megosh et al., 1995).
Because Odc is the rate-limiting enzyme of polyamine biosyn-
thesis, we predicted that Odc would be overexpressed in B cell
lymphomas that arise in E-Myc transgenic mice and in BL.
We therefore determined the levels of Odc protein in precan-
cerous B cells from 4- to 6-week-old E-Myc mice and their
wt littermates as well as in lymphomas that arise in E-Myc
transgenics. As expected from the RNA analyses, B220+ pre-
cancerous E-Myc B cells overexpressed Odc protein, and
even higher levels of Odc were present in lymphomas (Figure
1C). Furthermore, 8/14 primary tumors from patients suffering
from BL also overexpressed Odc transcripts (Figure 1D). There-
fore, Odc overexpression is a trademark of Myc-driven lym-
phomas in mice and humans.
Disrupting Odc function impairs
Myc-induced lymphomagenesis
Targeted deletion of Odc in mice leads to early embryonic le-
thality (Pendeville et al., 2001). However, Odc+/− mice appear
completely normal, despite the fact that they express half the
levels of Odc protein and enzyme activity (Guo et al., 2005).
We therefore addressed whether loss of one Odc allele would
affect Myc-induced lymphoma development. Odc+/− mice were
bred onto a C57Bl/6 background (12 generations) and were
then crossed to C57Bl/6 E-Myc transgenics. E-Myc;Odc+/+
and E-Myc;Odc+/− littermates were then followed for their
course of disease. As expected (Eischen et al., 1999), most
E-Myc;Odc+/+ mice succumbed to lethal lymphoma between
3 and 6 months of age (mean latency of 110 days, Figure 2A).CANCER CELL : MAY 2005
A R T I C L EFigure 1. Odc and other genes encoding en-
zymes in the polyamine biosynthetic pathway
are targeted by Myc in vivo
A: Affymetrix gene array showing expression of
the indicated genes in B220+ splenic B cells from
4- to 6-week-old wild-type (wt) and E-Myc litter-
mates. Probe sets with an asterisk are genes
that are significantly altered according to
Anova analysis (p < 0.05).
B: SYBRgreen real-time PCR analysis on cDNA
from bone marrow-derived (BM) B cells and
from splenic IgM+ B cells using primers for the
indicated genes. For the role of each individual
gene product in polyamine synthesis or catabo-
lism, see Supplemental Figure S1. The expression
of each gene was correlated to that of ubiquitin
(ub), which is not regulated by c-Myc. Mean ex-
pression is shown, and error bars represent
analyses of three individual mice of each ge-
notype.
C: Western blot analysis for Odc and Actin pro-
tein levels in B220+ MACS-sorted B cells from
6-week old wt and E-Myc (E) mice and in lym-
phomas arising in E-Myc mice.
D: SYBRgreen real-time PCR analysis on cDNA
from peripheral CD19+ B cells of a healthy donor
and from tumors of Burkitt’s lymphoma (BL) pa-
tients using primers directed against Odc. The
expression of Odc was correlated to that of
Ubiquitin, which is not regulated by c-Myc. An
asterisk indicates tumors with statistically signifi-
cant changes in the expression of Odc (Stu-
dent’s t test, p < 0.05).Strikingly, their E-Myc;Odc+/− littermates had a markedly de-
layed course of disease (mean latency of 320 days), and
w25% of these animals survived beyond 14 months of age
(Figure 2A). Hallmarks of imminent disease in E-Myc trans-
genics are elevated peripheral B cell counts and splenomegaly.
8-week-old E-Myc;Odc+/− mice had reduced numbers of pe-
ripheral B cells and smaller spleens compared to their E-
Myc;Odc+/+ littermates (data not shown). The delay in lym-
phoma development was not due to overt effects on lymphoid
cells in Odc+/− mice, as their B cell subsets and numbers were
normal (Table S1). Therefore, although halving the gene dosage
of Odc has no overt effect on development, modest reductions
in Odc activity markedly compromise Myc-mediated tumori-
genesis.
The effects of Odc heterozygosity suggested that lymphoma
development in E-Myc mice would also be impaired by treat-CANCER CELL : MAY 2005ing mice with DFMO, an enzyme-activated suicide inhibitor of
Odc (Cohen, 1997). Originally developed in the 1970s as a po-
tential therapeutic, DFMO irreversibly inactivates Odc in a
highly specific manner. DFMO is stable in water and is there-
fore easily administered to mice in their drinking water (Fozard
et al., 1980). Importantly, treatment of E-Myc mice with 1%
DFMO, from weaning age on, dramatically delayed lymphoma-
genesis (mean latency of w350 days) compared to littermates
provided with normal drinking water (mean latency of w100
days, Figure 2B). DFMO had no effect on the peripheral blood
counts or spleen size in wt mice, yet its effects on E-Myc
mice were dramatic, as 6–8 week old, DFMO-treated E-Myc
mice had normal white blood cell counts and lacked the sple-
nomegaly that was evident in untreated E-Myc mice (Figure
2C and data not shown). Finally, DFMO was continuously re-
quired to prevent lymphoma development, as when animals435
A R T I C L EFigure 2. Targeting Odc impairs Myc-induced lymphomagenesis
A: Survival curve of E-Myc mice of different Odc genotypes. Median sur-
vival time was 110 days for E-Myc;Odc+/+ and 320 days for E-Myc;
Odc+/− mice (p < 0.0001).
B: Survival curve of untreated (H2O) or DFMO-treated E-Myc mice. Mean
survival time for control mice was 100 days and those on DFMO was 350
days (p < 0.0001). The red arrow indicates the time at which a group of
DFMO-treated E-Myc mice were taken off the drug, and the red line indi-
cates their survival time after removal of DFMO (mean survival time 100
days).
C: Average spleen weights (n = 3) of 7-week-old wt and E-Myc mice
treated or untreated with DFMO. The treatment lasted for three weeks.
Student’s t test was employed for statistical analyses.treated with the drug for 90 days were then taken off from
DFMO they all succumbed to lymphomas. Furthermore, the
onset of the tumors in animals taken off the drug occurred at
the expected interval (3–4 months, red line Figure 2B). Collec-
tively, these findings support a crucial role for Odc in Myc-
induced lymphomagenesis.
Polyamine levels are in large part regulated by Odc activity
but are also controlled by polyamine catabolism and active
transport. The latter is carried out by a largely unknown mecha-436nism, but in most cells, polyamine transport is enhanced in
response to DFMO (Seiler et al., 1996). Endogenous stores of
polyamines are available from standard diets, and thus it was
somewhat surprising that the effects of DFMO on disease in
E-Myc mice were so profound. We therefore assessed
whether E-Myc transgenic B cells might be defective in poly-
amine uptake. Primary B cells were grown from precancerous
E-Myc bone marrow cells on S17 stroma in the presence of
IL-7 (Eischen et al., 1999), and afterw2 weeks in culture, these
cells were >95% pre-B cells, as determined by FACS with
B cell-specific markers. These cells, and control 32D.3 myeloid
cells (Askew et al., 1991), were then tested for effects of DFMO
on polyamine uptake. As expected, DFMO treatment of 32D.3
cells enhanced polyamine uptake (w2-fold). Surprisingly, DFMO
treatment reduced, rather than increased, polyamine uptake in
B cells from E-Myc mice (Figure 3A). Therefore, the B cells of
E-Myc transgenic mice are unable to compensate for reduc-
tions in Odc by increasing polyamine uptake.
Because Myc augments the expression of every enzyme in-
volved in polyamine biosynthesis (Figure 1), an expectation
was that polyamine levels would be elevated in B cells from
E-Myc mice. Indeed, elevated levels of putrescine, spermi-
dine, and spermine were evident in the precancerous B cells
of E-Myc transgenic mice versus those of their wt littermates
(Figure 3B). Furthermore, a 2-week exposure of mice to DFMO
effectively reduced levels of putrescine in bone marrow (data
not shown) and splenic transgenic B cells to those present in
wt littermates. DFMO treatment also resulted in significant re-
ductions in spermidine content but to compensatory increases
in spermine levels in both wt and E-Myc B cells (Figure 3B).
Nonetheless, the collective effect of DFMO on putrescine and
spermidine levels clearly counterbalances the biological effects
of increased polyamine levels seen in response to Myc.
Odc is a critical regulator of Myc’s proliferative response
In most cell lines, polyamine depletion induces G1 phase cell
cycle arrest (Cohen, 1997). Myc accelerates cell cycle pro-
gression and increases proliferative rates in vivo (Baudino et
al., 2003) and overrides cell cycle arrest in response to growth
factor withdrawal (Askew et al., 1991). We therefore evaluated
whether impairing Odc function would compromise Myc’s abil-
ity to drive B cell proliferation in vivo. Four different cohorts of
mice (wt untreated, wt + DFMO, E-Myc untreated, and E-
Myc + DFMO) were injected with BrdU, and after 12 hr, B cells
were isolated from bone marrow and spleen. The numbers of
BrdU+ and Annexin V+ IgM+ and IgM− negative splenic and
bone marrow-derived B cells were then determined. There
were much greater numbers of B cells in S phase in E-Myc
than in wt mice (Figure 4A). Although DFMO had essentially no
effect on the proliferative rates of B cells from wt mice, DFMO
treatment significantly reduced numbers of BrdU+ cells in all B
cell subpopulations of E-Myc transgenic mice, especially
those of proliferating IgM− splenic B cells (Figure 4A). A similar
reduction in BrdU+/IgM− splenic B cells was also evident in B
cells derived from E-Myc;Odc+/− mice compared to their wt
littermates (Figure 4B). Therefore, DFMO treatment, or loss of
one allele of Odc, impairs Myc’s proliferative response.
In contrast to the obvious effects of DFMO and Odc hetero-
zygosity on Myc’s proliferative response, the effects of impair-
ing Odc on Myc-induced apoptosis were not as evident. In E-
Myc mice, Myc’s apoptotic response is mostly manifest in IgM+CANCER CELL : MAY 2005
A R T I C L EFigure 3. DFMO-treatment reduces polyamine uptake in E-Myc B cells
and restores proper levels of putrescine in E-Myc transgenic B cells in vivo
A: Bone marrow cells from an E-Myc mouse were cultured ex vivo on S17
stromal cells in medium containing IL-7. After establishment of a pure B cell
culture, 106 cells were cultured in the presence (D) or absence (C) of
DFMO for two days. 3H-spermidine was added, and the cells were incu-
bated for 1 hr at 37°C or on ice (I). Uptake of spermidine was determined
with a scintillation counter. The experiment was carried out in triplicates. As
a control, IL-3-dependent 32D.3 myeloid cells (Askew et al., 1991) were
also analyzed. Student’s t test was employed for statistical analyses.
B: Effects of DFMO on polyamine levels in splenic B cells in vivo. Levels of
intracellular putrescine, spermidine, and spermine were determined in 106
splenic B cells from untreated (C) and DFMO-treated (D) 4- to 6-week-old
wt (squares) and E-Myc (filled arrowheads) mice. Five to six mice of each
group were analyzed. Black symbols, untreated mice; red symbols, DFMO-
treated mice.B cells (Maclean et al., 2003). DFMO had no effect on the sur-
vival of wt B cells, and it did not impair Myc-induced apopto-
sis; rather, the higher rates of apoptosis of E-Myc IgM-posi-
tive B cells were enhanced in DFMO-treated transgenics
(Figure 4B). Furthermore, analyses of the apoptotic index of
E-Myc;Odc+/− transgenic B cells, and of wt Odc+/− B cells,
indicated that Odc heterozygosity had no effect on B cell sur-
vival. Collectively, these findings support the concept that Odc
is selectively haploinsufficient for Myc’s proliferative response.
Odc is necessary for Myc-mediated suppression
of p21Cip1 and p27Kip1
Myc-driven tumors are dependent on sustained Myc expres-
sion (Jain et al., 2002; Pelengaris et al., 1999). Given the pro-CANCER CELL : MAY 2005found effect of Odc heterozygosity or DFMO treatment on lym-
phomagenesis, we initially assessed whether compromising
Odc activity would affect the expression of the Myc transgene
in E-Myc B cells. However, expression profiling and real-time
PCR of splenic B220+ B cells (Figures 5A and 5B), and Western
blot analyses of B220+ B cells from bone marrow (data not
shown) and spleen (Figures 6A and 6B), established that Myc
activity was sustained in E-Myc mice treated with DFMO (Fig-
ure 6A) or when crossed onto a Odc heterozygous background
(Figure 6B). To analyze the expression of Myc target genes
(http://www.myccancergene.org), we clustered those genes
that differed significantly between splenic B cells from 7-week-
old wt and E-Myc mice (three mice per group). Their expres-
sion profiles were then compared to those of wt and E-Myc
littermates treated with DFMO for 3 weeks. These analyses
established that the Myc transgene, rather than DFMO, was
the major determinant of changes in the expression of these
targets (Figure 5A). In addition, real-time PCR analyses estab-
lished that the increased levels of c-myc, odc, and rcl tran-
scripts in E-Myc B cells were not appreciably affected by
DFMO treatment, and loss of one allele of Odc only affected
odc levels (Figure 5B). Therefore, impairing Odc function does
not alter the expression of the Myc transgene nor its ability to
regulate the majority of its transcription targets.
Myc’s proliferative response has been associated with its
ability to regulate cyclins and their kinases. Indeed, levels of
cyclin D1 (ccnd1), cdk4, and cdk2 were upregulated in E-Myc
B cells, but they were unaffected by DFMO treatment (Figure
6D), and expression of cyclin D2, a direct target of Myc in some
cell contexts (Bouchard et al., 1999), was reduced in E-Myc
B cells and unaffected by DFMO (data not shown). Further-
more, the expression of cyclin E1 and E2 and cyclin A were
not significantly altered by Myc or by treatment with DFMO
(data not shown). However, Myc also accelerates cell cycle tra-
verse by suppressing the expression of the cdk inhibitors
p21Cip1 and p27Kip1, and indeed, levels of p21Cip1 and p27Kip1
were repressed in B220+ precancerous splenic B cells of E-
Myc mice (Figures 6A and 6B). DFMO, or loss of one Odc
allele, had only very subtle effects on the expression of
these Cdk inhibitors in B cells derived from wt mice (Figures
6A and 6B). Strikingly, levels of p21Cip1 and p27Kip1 protein
were effectively restored back to those present in wt splenic B
cells in E-Myc mice treated with DFMO and in E-Myc;
Odc+/− mice (Figures 6A and 6B). Expression profiling indicated
that the changes in at least p27Kip1 expression were manifest
at the level of the protein and not its RNA, as levels of cdkn1b
transcripts (encoding p27Kip1) remained low in B cells from
DFMO-treated E-Myc mice (Figure 6D). Furthermore, DFMO
treatment of primary pre-B cells engineered to express a condi-
tionally activatable form of Myc, Myc-ER, induced p27Kip1 pro-
tein (Supplemental Figure S2A) without affecting the levels of
ckn1b transcripts, which were suppressed after Myc activation
with the estrogen receptor (ER) agonist 4-hydroxytamoxifen
(Supplemental Figure S2B). The level at which disabling Odc
leads to changes in p21Cip1 expression was less evident, as
expression profiling called cdkn1a (encoding p21Cip1) as ab-
sent and acute treatment of Myc-ER-expressing pre-B cells
with DFMO had little effect on p21Cip1 protein levels (Supple-
mental Figure S2A). Therefore, impairing Odc abolishes Myc’s
ability to downregulate p27Kip1 protein and, perhaps through
indirect means, p21Cip1 protein. Alternatively, disabling Odc437
A R T I C L EFigure 4. DFMO and Odc heterozygosity impair
Myc’s proliferative response
A: Effects of DFMO and Odc heterozygosity on
Myc-driven B cell proliferation in vivo. Bone mar-
rows and spleens from untreated (C) and
DFMO-treated (for 3 weeks) (D) wt and E-Myc
mice were harvested 12 hr after BrdU injection
(at 7 weeks of age). Three mice of each group
were analyzed for BrdU incorporation in B220+/
surface IgM- and B220+/IgM+ cells; i.e., pro/pre
B cells and more mature B cells (black bars, wt
IgM−; dark gray, wt IgM+; black stippled, wt IgM+
DFMO-treated; gray stippled, wt IgM− DFMO-
treated; light gray, E-Myc IgM−; red, E-Myc
IgM+; light gray hatched, E-Myc IgM− DFMO-
treated; and red hatched, E-Myc IgM+ DFMO-
treated). B cell proliferation of 8-week-old wt
and Odc+/− E-Myc transgenics were analyzed
in a similar fashion (gray checkered bars, E-
Myc;Odc+/− IgM−; red checkered, E-Myc;
Odc+/− IgM+). Student’s t test was employed for
statistical analyses.
B: To determine apoptotic indices, aliquots of
the same bone marrow and spleen samples as
in (A) were stained for B220, IgM, and Annexin
V. Student’s t test was employed for statistical
analyses.may induce p27Kip1 and p21Cip1 protein through a pathway in-
dependent of Myc.
The very modest effects of DFMO and Odc heterozygosity
on Myc’s apoptotic response in vivo suggested that compro-
mising Odc function would not alter Myc’s ability to activate
the Arf-p53 pathway. As expected (Eischen et al., 1999), there
was an obvious upregulation of p19Arf and p53 protein in B
cells derived from both bone marrow and spleen of precancer-
ous E-Myc mice compared to their wt littermates (Figure 6C
and data not shown). Further, DFMO treatment (or Odc hetero-
zygosity, data not shown) did not augment this response but
slightly reduced levels of p19Arf and p53 in E-Myc B cells
(Figure 6C). Finally, Myc-induced apoptosis has also been as-
sociated with its ability to induce the expression of the pro-
apoptotic Bcl-2 family proteins Bax (Mitchell et al., 2000) and
Bim (Egle et al., 2004). Bax expression was comparable in wt
and E-Myc transgenic B cells +/− DFMO, and Bim expression
also did not correlate with effects of DFMO treatment (Figure
6C and data not shown). Therefore, impairing Odc functions
does very little to Myc’s apoptotic response.
Impairing Odc functions alters the route
of Myc-induced transformation
Hallmarks of tumors that arise in E-Myc transgenics are alter-
ations in the Arf-p53 tumor suppressor pathway, which occur
through missense hot-spot mutations of p53 that create domi-438nant negative forms of the protein, and biallelic deletion of Arf
(Eischen et al., 1999). Unlike wt p53, dominant negative p53
mutants have a long half-life, and tumors bearing p53 muta-
tions express high levels of endogenous p19Arf, due to loss of
p53-mediated transcriptional repression of Arf (Robertson and
Jones, 1998). Collectively, Western and Southern blot analyses
indicated that the frequency of alterations in the Arf-p53 path-
way was only slightly reduced in lymphomas arising in E-
Myc;Odc+/− mice versus their wt E-Myc littermates (Figures
7A and 7B). However, tumors arising in E-Myc;Odc+/− mice
lacked deletions of Arf (Figure 7B, bottom), whereas 4/9 lym-
phomas arising in their E-Myc littermates showed biallelic
deletions in Arf (lanes with an asterisk, Figure 7B, top). Lym-
phomas that ultimately arose in DFMO-treated E-Myc trans-
genics also lacked Arf deletions (data not shown). Thus, im-
pairing Odc specifically biases against biallelic deletions in Arf
during Myc-induced transformation.
Impairing Odc activity abolished Myc’s ability to downregu-
late the expression of p21Cip1 and p27Kip1 (Figures 6A and 6B).
We therefore assessed the expression of these cdk inhibitors
in the lymphomas that arose in E-Myc;Odc+/− versus E-
Myc;Odc+/+ littermates. Very low to undetectable levels of
p21Cip1 and p27Kip1 protein were present in lymphomas arising
in wt E-Myc transgenics, yet the levels of these inhibitors
were markedly elevated in many of the tumors arising in E-
Myc;Odc+/− transgenics (Figure 7A). Furthermore, the levels ofCANCER CELL : MAY 2005
A R T I C L EFigure 5. DFMO treatment and Odc heterozy-
gosity do not affect Myc’s transcriptional re-
sponse
A: DFMO does not grossly affect the “Myc tran-
scriptome.” Hierchical clustering of significantly
altered genes of the Myc target gene data-
base is presented. RNA was prepared from
B220+ splenic cells of 7-week-old untreated and
DFMO-treated (3 weeks) wt and E-Myc mice
and was subjected to analysis on a 430A Affy-
metrix chip (three mice were analyzed per
group). Analysis was performed with the “treat-
ment comparison” function of the Spotfire pro-
gram. The gene names of the probe sets shown
are given in Supplemental Table S3.
B: SYBRgreen real-time PCR analysis on cDNA
from splenic B cells of wt, Odc+/−, E-Myc and
E-Myc;Odc+/− mice, and wt and E-Myc mice
treated with DFMO (for 2 weeks) was performed
with primers (Supplemental Table S2) for c-myc
and the direct Myc transcription targets odc
and rcl. The expression of each gene was stan-
dardized to that of ub. Mean expression is
shown, and error bars represent analyses of
three individual mice of each genotype.the antiapoptotic protein Bcl-XL, which is only rarely increased
in lymphomas arising in E-Myc transgenics (Eischen et al.,
2001a), were markedly elevated in several tumors arising in E-
Myc;Odc+/− transgenics (Figure 7A). Finally, we evaluated
whether there might be a selection for alterations in the Odc
gene (for example Odc amplification) in tumors arising in E-
Myc;Odc+/− transgenics. However, neither of these events was
evident (Supplemental Figure S3). Therefore, the delay in tumor
development in E-Myc;Odc+/− transgenics is associated with
specific differences in the expression of p21Cip1, p27Kip1, and
Bcl-XL and with a lack of deletions in Arf.
The failure of lymphomas arising in E-Myc;Odc+/− and
DFMO-treated E-Myc mice to undergo alterations in Arf sug-
gested that in cells where Arf function is compromised, the
preventative effects of DFMO might be abolished. To test this
notion, we bred E-Myc mice to ArfGFP/GFP mice (Zindy et al.,
2003), an Arf knockout strain that bears the gene for green
fluorescent protein (GFP) in place of exon 1β of Arf in the Ink4a/
Arf locus. E-Myc;Arf+/− transgenic mice develop lymphomas
at a greatly accelerated pace, and this is nearly always accom-
panied by loss of the remaining wt Arf allele, as expected for
a tumor suppressor gene (Eischen et al., 1999). Indeed, all E-
Myc;Arf+/GFP died within 2.5 months of age (Figure 7C) and
4/5 of the lymphomas arising in these mice lost the wt Arf allele
(Figure 7D). Strikingly, DFMO treatment (from 1 week of age)
failed to significantly delay lymphoma development in E-
Myc;Arf+/GFP littermates (Figure 7C), and tumors that arose inCANCER CELL : MAY 2005these mice all displayed loss of the wt Arf allele (Figure 7D).
Therefore, disabling Odc delays the onset of de novo deletions
of Arf, but not gene conversions, in ArfGfp/+ mice. Importantly,
these data indicate that targeting Odc is effective as a chemo-
preventative intervention but would be ineffective in therapy for
cancers bearing mutations in the Arf-p53 tumor suppressor
pathway.
Discussion
Chemoprevention strategies targeting the polyamine biosyn-
thetic pathway in cancer have recently shown efficacy in a
number of preclinical animal studies and also appear to show
promise in clinical trials in human cancer (Gerner and Meyskens,
2004). However, the mechanisms by which targeting Odc pre-
vents cancer have been a mystery. The findings reported herein
provide clues to this puzzle and reveal that targeting Odc pre-
vents Myc-induced tumorigenesis in two ways. First, Odc is
necessary for Myc to accelerate cell cycle traverse. This re-
sponse is specifically linked to Myc’s effect on the Cdk inhibi-
tors p21Cip1 and p27Kip1, as when Odc is disabled, Myc’s abil-
ity to suppress their expression is effectively counteracted.
Second, although Odc does not overtly affect Myc’s apoptotic
response, full activity of the enzyme appears critical for events
that lead to the biallelic deletions in Arf that often accompany
Myc-induced lymphomagenesis, and compromising the Arf
checkpoint inactivates Odc inhibitors as chemopreventative439
A R T I C L EFigure 6. DFMO treatment and Odc heterozygosity abolishes Myc’s ability
to suppress the expression of the Cdk inhibitors p21Cip1 and p27Kip1
A: Western blot analysis of p21Cip1 and p27Kip1 expression in spleen-derived
B220+ B cells. The protein samples were from untreated (C) and DFMO-
treated (3 weeks) (D) wt and E-Myc mice.
B: Western blot analysis of p21Cip1 and p27Kip1 expression in spleen-derived
B220+ B cells from wt, Odc+/−, E-Myc, and E-Myc;Odc+/− (8-week-old) lit-
termates.
C: Western blot analysis of p53, p19Arf, and Bax expression in spleen-
derived B220+ B cells. The protein samples were again from untreated (C)
and DFMO-treated (3 weeks) (D) wt and E-Myc mice.
D: Affymetrix gene array showing expression of the indicated genes in
B220+ splenic B cells from 4- to 6-week-old wt and E-Myc littermates un-
treated (C) or treated with DFMO for 2 weeks.440Figure 7. Targeting Odc alters the route of Myc-induced transformation
A: Western blot analysis of p53, p19Arf, p21Cip1, p27Kip1, and Bcl-XL expres-
sion in lymphomas arising in Eu-Myc and Eu-Myc;Odc+/− littermates.
B: Southern blot hybridization of genomic DNA from the same tumors as in
(A) using a probe against the Arf locus. An asterisk indicates tumors show-
ing biallelic deletion of Arf in Eu-Myc transgenics; two asterisks indicate a
tumor undergoing alterations of one allele of Arf.
C: Survival curve of five untreated (H2O) or five DFMO-treated Eu-Myc;
Arf+/GFP mice.
D: Southern blot hybridization of genomic DNA from tumors arising in Eu-
Myc;Arf+/GFP mice. The top band represents the targeted, GFP-containing
allele and the lower band the wt allele that is lost during tumorigenesis.agents. These findings underscore the limitations of targeting
Odc in cancer, where DFMO is effective as a chemopreventa-
tive agent but has largely failed as a cancer therapeutic (Gerner
and Meyskens, 2004). Nonetheless, the rather remarkable ef-
fects of DFMO or loss of one Odc allele in preventing Myc-
induced lymphomagenesis establish Odc as one of the critical
downstream targets of Myc that is necessary to drive cell pro-
liferation and transformation.
Not all Myc targets are created equal
Mouse models such as E-Myc transgenics provide valuable
platforms to test the relevance of known downstream targets
of oncogenes and/or tumor suppressors that may contribute
to cancer development and/or maintenance. Based upon their
ability to drive quiescent cells into cycle and to accelerate rates
of cell cycle progression, critical targets of Myc were initially
thought to be those that regulate the cell cycle. More recent
in vivo assessments have shown that proposed Myc targets
like Id2 (Murphy et al., 2004; Nilsson et al., 2004b), Cyclin D2
(P. Sicinski and M. Eilers, personal communication), and Cdk4
(J.A.N. and J.L.C., unpublished data) are dispensable for Myc-induced tumorigenesis. However, there are obvious cell con-
text-specific effects of these regulators as in the K5-Myc trans-
genic mouse model loss of Cdk4 impairs skin tumorigenesis
(Miliani de Marval et al., 2004), and loss of E2f1, which is also
induced by Myc (Baudino et al., 2003), accelerates Myc-
induced skin tumors (Rounbehler et al., 2002), yet impairs Myc-
induced lymphomagenesis.
Characterization of the Myc transcriptome by SAGE, expres-
sion profiling, and genome-wide scans for sites of Myc bound
chromatin have indicated that the majority of Myc targets are
those thought to direct cell metabolism, cell growth (mass),
and the ribosome machinery (Patel et al., 2004). The numbers
of Myc targets that have come from these assays range up
into the thousands (Patel et al., 2004), suggesting that focusing
efforts on any single Myc target would be ineffective. Thus, our
finding that intervention of a single metabolic target of Myc
impairs lymphomagenesis is remarkable and suggests that theCANCER CELL : MAY 2005
A R T I C L Edownstream products of Odc, the polyamines, influence many
of the metabolic and growth processes that are also necessary
for cell division and transformation.
This study suggests that metabolic targets of Myc certainly
deserve attention as targets in cancer chemoprevention and
therapy. The case for targeting Odc is particularly compelling.
Firstly, Odc expression is induced by various carcinogens (Co-
hen, 1997), and Odc overexpression is sufficient to induce
transformation in vitro (Auvinen et al., 1992) and for tumor pro-
motion in the skin (O’Brien et al., 1997). Secondly, Odc-
induced tumorigenesis is reversed by DFMO treatment (Lan et
al., 2000). Further, in addition to its impressive effect on E-
Myc transgenics, DFMO is also effective in blocking tumorigen-
esis in other mouse cancer models but heretofore has never
been formally linked to a pathway leading to changes in Odc
expression. Thirdly, overexpression of antizyme, which directs
Odc to the proteasome for destruction (Murakami et al., 1992),
blocks tumorigenesis (Feith et al., 2001). Fourthly, a single-
nucleotide polymorphism in human ODC that resides between
the two Myc-Max sites in ODC intron 1 regulates its expression
(Guo et al., 2000) and correlates with improved clinical re-
sponse in colon adenomas (Martinez et al., 2003). Finally, as
shown here, and also in skin tumor models (Guo et al., 2005),
Odc heterozygosity dramatically impairs tumorigenesis. There-
fore, critical thresholds of Odc, and thus of polyamines, are
important arbiters of tumor development. Indeed, simply re-
ducing levels of putrescine to those present in wt B cells is
sufficient to markedly impair lymphoma development.
Odc mediates Myc’s proliferative response
and directs the route of transformation
Perturbing Odc functions affects the Myc response at two
levels. DFMO treatment or Odc heterozygosity abolishes the
ability of Myc to accelerate B cell cycle traverse (Figure 4B),
and this occurs without gross effects on Myc’s transcriptional
programs (Figure 5A). Rather, impairing Odc abolishes the abil-
ity of Myc to suppress the expression of p21Cip1 and p27Kip1
(Figures 6A and 6B and Supplemental Figure S2). Although
Myc can repress the transcription of both Cdkn1a (p21Cip1) and
Cdkn1b (p27Kip1) (Gartel et al., 2001; Herold et al., 2002; Yang
et al., 2001), in the E-Myc B cell, the regulation of at least
p27Kip1 appears to occur largely at a posttranscriptional level,
as expression profiling and real-time PCR failed to document
changes in cdkn1b transcripts in response to DFMO treatment
(Figure 6D and Supplemental Figure S2). Degradative control
is an important route of regulating p21Cip1 and p27Kip1 protein
levels (Bartek and Lukas, 2001; Sherr and Roberts, 1999), and
this level of regulation for p27Kip1 is certainly important in the
response to Myc (O’Hagan et al., 2000; Vlach et al., 1996). The
ability of DFMO or Odc heterozygosity to effectively abolish
this response thus suggests that changes in the thresholds of
polyamines may also influence the turnover of these proteins,
which is consistent with studies showing that polyamine deple-
tion can lead to the induction of p21Cip1 (Kramer et al., 2001).
Importantly, a limiting role for p27Kip1 in B cell transformation
in E-Myc transgenic mice has already been established, as
loss of p27Kip1, but not of p21Cip1, accelerates lymphomagen-
esis (Martins and Berns, 2002), and loss of E2f1 leads to the
ectopic expression of p27Kip1 and delays lymphomagenesis
(Baudino et al., 2003). Thus, DFMO’s chemopreventative prop-CANCER CELL : MAY 2005erties likely include its ability to specifically restore p27Kip1,
which would suppress tumor development.
When faced with the inability to downregulate p21Cip1 and
p27Kip1, such as occurs in E-Myc;Odc+/− mice, alternative
routes of transformation appear to be at play. Quite dramati-
cally, very low to undetectable levels of p21Cip1 and p27Kip1
were revealed as a hallmark of lymphomas arising in E-Myc
transgenics, and Myc’s ability to suppress their expression was
abolished in many tumors arising in E-Myc;Odc+/− trans-
genics. In addition, many of the lymphomas arising in these
mice were also characterized by a marked upregulation of Bcl-
XL, a rare event in these tumors (Eischen et al., 2001a). Further-
more, although impairing Odc has no overt effects on Myc’s
apoptotic response in vivo, a striking finding was that none of
the tumors arising in E-Myc;Odc+/− or DFMO-treated E-Myc
transgenics bore biallelic deletions in Arf, which were readily
evident in lymphomas arising in wt E-Myc transgenics (Figure
7B). Finally, loss of even one Arf allele was sufficient to render
E-Myc B cells refractory to the protective effects of DFMO
(Figure 7C). Thus, the ability of DFMO or Odc heterozygosity
to impair transformation appears to occur at a very early step
and likely involves blocking of lesions that provoke the loss of
one allele of Arf, which can sometimes be captured in E-Myc
lymphomas (e.g., see the lane with two asterisks, Figure 7B),
that then lead to loss of the entire Arf locus.
Relevance to human cancer
Myc oncoproteins are deregulated in the vast majority of hu-
man tumors, suggesting they are perfect targets for chemo-
therapeutic intervention. Unfortunately, their functions as tran-
scription factors that regulate a large fraction of the genome
clearly complicate this approach. Further, Myc is a member of
the “Max network,” where Max also dimerizes with at least six
other partners to repress transcription (Eisenman, 2001), and
Myc-induced target gene activation may rely on its ability to
relieve Mnt-Mad-mediated transrepression (Nilsson et al.,
2004a). Therefore, targeted therapies that block Myc binding
to E boxes may also block Mnt-Mad functions and lead to acti-
vation of gene transcription through relief of transrepression,
the opposite of the desired effect. We therefore propose that
targeting the products of genes induced by Myc is a safer ap-
proach to treating Myc-driven tumors. Focusing on those gene
products that are enzymes, like Odc, should facilitate drug
design.
Myc-driven tumors require sustained expression of the on-
cogene and quickly regress when Myc activity is compromised
(Jain et al., 2002; Pelengaris et al., 1999). If Odc were also a
key mediator of Myc in tumor maintenance, then treatment of
preexisting lymphomas with DFMO would be predicted to be
of therapeutic benefit. However, we and others (Gerner and
Meyskens, 2004) have seen little, if any, effect of DFMO on
the progression of established malignancies. Still, DFMO as a
chemopreventative agent is important in many scenarios of hu-
man cancer where tumors arise in a predictable manner. For
example, in colon cancer, which undergoes an ordered pro-
gression from polyps to adenomas to frank carcinoma, combi-
nations of COX-2 inhibitors with DFMO have proven efficacious
in preventing adenoma recurrence and progression to carci-
noma (Gerner and Meyskens, 2004). This represents a success
story, but there are many as yet unexplored arenas that repre-
sent avenues for prevention. Finally, there is a growing cadre441
A R T I C L Eof heritable malignancies where agents such as DFMO, which
has limited toxicity, should be considered. We have shown that
DFMO is effective at blocking tumor formation in a scenario
where there is a single genetic lesion (Myc activation). There-
fore, it is possible that this agent will also be effective in block-
ing secondary mutations occurring in heritable breast and
ovarian cancer patients having mutations of BRCA1, BRCA2,
or CHK2 and in Li-Fraumeni patients having TP53 mutations
(Varley, 2003).
Experimental procedures
Mice and tumor analyses
Odc+/− mice were bred with E-Myc transgenics (both on C57Bl/6 back-
ground) to generate F1 E-Myc;Odc+/− and E-Myc;Odcwt offspring. E-
Myc transgenic male mice were also bred to ArfGFP/GFP knockin/knockout
females (mixed background, kindly provided by Drs. Martine Roussel and
Charles Sherr) to generate E-Myc;Arf+/GFP mice (Zindy et al., 2003). Lastly,
cohorts of E-Myc transgenic mice were given either standard water or
water containing 1% DFMO. All mice were observed daily for signs of mor-
bidity and tumor development. Sick animals were sacrificed, and tumors
and lymphoid organs were analyzed by histology and immunohistochem-
istry to confirm B cell lymphoma.
With institutional review board approval and after informed consent, RNA
was extracted from tumors of 14 BL patients by using the RNA/DNA Kit
from Qiagen.
Cell culture
Primary bone marrow-derived pre-B cell cultures were generated from
6-week-old C57Bl/6 mice as described (Eischen et al., 1999). After 2 weeks
in culture on S17 stromal cells, the established B cell culture was main-
tained in conditioned medium from NIH-3T3 cells expressing IL-7. To test
effects of DFMO on polyamine transport, cells were cultured in the presence
of 5 mM DFMO for 2 days. IL-3-dependent 32D.3 myeloid cells were cul-
tured as previously described (Askew et al., 1991). Generation of pre-B cell
cultures expressing Myc-ER has been described (Nilsson et al., 2004b).
Polyamine transport
1 × 106 B cells or 32D.3 cells (Askew et al., 1991) were cultured ± 5 mM
DFMO for 2 days. 1 l 3H-spermidine was added and the cells incubated
for 1 hr at 37°C or on ice (negative control for nonspecific binding). After
incubation, the cells were harvested, washed twice with PBS containing
100 M cold spermidine, and lysed by the addition of 1 M NaOH. The lysate
was mixed with scintillation fluid (UltimaGold, Packard Bioscience) and
counted in a scintillation counter.
B cells from untreated and DFMO-treated wt and E-Myc transgenic
mice were analyzed for their polyamine content by high-performance liquid
chromatography. Briefly, polyamines from frozen pellets of 1 × 106 cells
were extracted with 0.6 N perchloric acid, dansylated, and analyzed as de-
scribed (Chen et al., 2001).
FACS and magnetic-activated cell sorting of B cells
Rates of proliferation of B220+/IgM+ and B220+/IgM− cells were determined
by using a Flow Kit as described by the manufacturer (BD Biosciences
Pharmingen). Animals were injected intraperitoneally with 100 l of 10 mg/
ml BrdU in sterile PBS. Animals were sacrificed 12 hr postinjection, and
bone marrow and spleen were harvested. 1 × 106 cells were used for the
BrdU proliferation assay, by incubation with antibodies against B220 (APC
conjugated) and IgM (PE conjugated), followed by washes. Labeled cells
were further processed and stained with FITC anti-BrdU antibody, washed,
and analyzed by FACS.
The remainder of the bone marrow and spleen cells was incubated with
beads conjugated to a B220 antibody (Miltenyi Biotech) and enriched by
MACS for B cells according to the manufacturer’s instruction. The same
procedure was used to obtain splenic B cells as controls for Western blots.
RNA preparation and analyses
B cells were obtained from bone marrow or spleen by MACS using beads
conjugated to antibodies against B220 or IgM, respectively. RNA was pre-442pared by using the RNeasy Kit (Qiagen). For Affymetrix analyses, cRNA was
synthesized by using the One-Cycle Target Labeling and Control Reagent
package (Affymetrix, Inc.), and the reaction was probed to the 430A mouse
Affymetrix chip. The scanned data output was imported into the Spotfire
software. After normalization, selected probe sets for genes indicated in
Figure 1 or in Figure 5 were clustered by using the Hierarchical Clustering
function of Spotfire. Statistical analysis was performed in Spotfire with the
Anova function.
For real-time PCR, cDNA was prepared from 1 g RNA by using the
iScript cDNA Synthesis Kit (Bio-Rad). Real-time PCR was performed with
an iCycler machine (Bio-Rad) and the iTaq SYBR Green Kit. Data analyses
were performed with the Ct method, where ubiquitin served as the internal
control. Sequences for primers are available in Supplemental Table S2.
Western blot analyses
Extracts from MACS-sorted B cells and lymphomas from E-Myc mice
were prepared as described (Eischen et al., 1999). Protein (30–50 g per
lane) was separated on a 15% SDS-PAGE gel, transferred to membranes
(Protran, Schleicher & Schuell), and blotted with antibodies specific for
c-Myc (N-262, Santa Cruz Inc.), ODC (from Drs. Anthony Pegg and Lisa
Schantz), p21Cip1 (F-5, Santa Cruz Inc.), p27Kip1 (Transduction labs), p53
(Ab-7, Oncogene research), p19Arf (Abcam), Bim (Stressgen Bioreagents),
Bax (Santa Cruz Inc.), and β-actin (AC-15, Sigma Chemicals).
Supplemental data
Supplemental Data include three figures and three tables and are available
with this article online at http://www.cancercell.org/cgi/content/full/7/5/433/
DC1/.
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